At the moment, Amgen looks like it has a sizeable lead in the DLL3 category, with other potential indications for tarlatamab, including neuroendocrine prostate cancer (in phase 1) and potentially ...
It is further described as a targeted therapy "designed to improve outcomes in patients who have tried all other treatment ...
Research presented at SABCS 2024 highlighted efforts to expand treatment options for early breast cancer as well as ...
Actuate Therapeutics (ACTU) announced data from its ongoing and fully enrolled randomized Phase 2 trial of elraglusib in combination with ...
Actuate Therapeutics (ACTU) announced new positive data from its ongoing and fully enrolled randomized Phase 2 trial of elraglusib in ...
Buy and Rent Property faster and better using our app.
News Medical on MSN4d
Revolutionizing MASLD treatment with GLP-1 receptor agonistsResearchers explore the therapeutic potential and clinical insights of GP1-RAs in the management of metabolic ...
The search for effective therapies in ulcerative colitis, a chronic inflammatory condition affecting the colon and rectum ...
What is the moon phase today? Today, Dec. 19, 2024, the moon is 17 days old, in the Waning Gibbous phase of its lunar cycle. It is 81% illuminated. Moon phases reveal the passage of time in the ...
GlobalData on MSN2d
Sanofi and Teva’s duvakitug meets primary endpoints in Phase IIb trialSanofi and Teva Pharmaceuticals have reported that the Phase IIb RELIEVE UCCD study of the human IgG1-λ2 monoclonal antibody ...
Meropenem 0.5-g a and 1-g b vials were used to prepare 4-mg/mL solutions. Each 0.5-g vial was reconstituted with 10 mL of sterile water for injection (SWFI) and each 1-g vial with 20 mL of SWFI to ...
The Southwest Oncology Group also recently reported S0435, a phase II study investigating the ... Patients with ES-SCLC treated with only 1 previous platinum-based chemotherapy regimen were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback